Written question asked by Tanmanjeet Singh Dhesi (Labour) on Monday, 9 January 2023, in the House of Commons. It was due for an answer on Wednesday, 11 January 2023. It was answered by Helen Whately (Conservative) on Monday, 16 January 2023 on behalf of the Department of Health and Social Care.
Breast Cancer: Chemotherapy
- Question
-
To ask the Secretary of State for Health and Social Care, for what reasons a review of the NICE diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer has not taken place.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is actively considering options for its diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. A number of technologies are recommended in the current guidance, provided data is collected to reduce uncertainties in the evidence base.
In line with its published process and methods, NICE routinely monitors for new information, such as changes to the evidence base, assessing its likely effect on current recommendations. NICE will only undertake a formal review to determine if an update to the guidance review if this is indicated by its monitoring activities.
Secondary information
- Type
- Written question
- Reference
- 119099
- Session
- 2022-23
- Grouped for answer
- Yes
- Subjects
- Breast cancer Genetics Screening Chemotherapy
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-01-16 18:20:44 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/119099
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/119099
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/119099